Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond (Record no. 39814)

MARC details
000 -LEADER
fixed length control field 02166naaaa2200337uu 4500
001 - CONTROL NUMBER
control field https://directory.doabooks.org/handle/20.500.12854/58773
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220219195059.0
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 978-2-88945-539-3
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9782889455393
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.3389/978-2-88945-539-3
Terms of availability doi
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title English
042 ## - AUTHENTICATION CODE
Authentication code dc
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Stefano Morotti
Relationship auth
245 10 - TITLE STATEMENT
Title Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Frontiers Media SA
Date of publication, distribution, etc. 2018
300 ## - PHYSICAL DESCRIPTION
Extent 1 electronic resource (385 p.)
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open Access
Source of term star
Standardized terminology for access restriction Unrestricted online access
520 ## - SUMMARY, ETC.
Summary, etc. Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of articles presenting new technological and conceptual advances, including refinement of ex vivo and in vitro assays, screens and models, and in silico approaches reflecting the increasing effort that has been put forward by regulatory agencies, industry, and academia to try and address the need of a more accurate, mechanistically-based paradigm of proarrhythmic potential of drugs. This Research Topic is dedicated to the memory of Dr. J. Jeremy Rice, our wonderful friend and colleague.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons
Use and reproduction rights https://creativecommons.org/licenses/by/4.0/
Source of term cc
-- https://creativecommons.org/licenses/by/4.0/
546 ## - LANGUAGE NOTE
Language note English
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term cardiotoxicity
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term cardiac electrophysiology.
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term drug-induced arrhythmia
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term QT interval prolongation
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term multi-scale modeling
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Eleonora Grandi
Relationship auth
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Esther Pueyo
Relationship auth
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Blanca Rodriguez
Relationship auth
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://www.frontiersin.org/research-topics/5662/safety-pharmacology---risk-assessment-qt-interval-prolongation-and-beyond">https://www.frontiersin.org/research-topics/5662/safety-pharmacology---risk-assessment-qt-interval-prolongation-and-beyond</a>
Access status 0
Public note DOAB: download the publication
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://directory.doabooks.org/handle/20.500.12854/58773">https://directory.doabooks.org/handle/20.500.12854/58773</a>
Access status 0
Public note DOAB: description of the publication

No items available.